Johnson & Johnson announces new data from Tremfya phase 3 QUASAR LTE study in adults with moderately-to-severely active ulcerative colitis: San Diego, California Tuesday, May 6, 2 ...

Two biosimilars developed under the Teva - Alvotech partnership have been granted FDA approval with interchangeability, including SELARSDI. In February 2024, the FDA approved SIMLANDI ® ...

Thetis Pharmaceuticals LLC ("Thetis"), a clinical-stage company developing TP-317, a first-in-class, small molecule drug candidate targeting the BLT1 receptor to treat inflammatory bowel disease (IBD) ...

In 2021, Sly, biochemistry professor Harry Brumer, and a group of other researchers at the UBC developed GlycoCage, a ...

The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.

Biocon Biologics' Yesintek, a biosimilar to Stelara, has secured significant market access in the US, covering over 100 ...

Black patients face higher complications related to inflammatory bowel disease than White patients, according to a study presented at DDW 2025.

In this Healio video, Edward L. Barnes, MD, MPH, associate professor of medicine, co-director of the Multidisciplinary IBD Center and associate fellowship program director at the University of North ...

Researchers and clinicians have developed major new guidelines for the monitoring of patients with inflammatory bowel disease ...

The Consortium Global IBD Visualization of Epidemiology Studies in the 21st Century (GIVES-21) published data on the global ...